Browse studies

Find your next paid study

4,610 recruiting studies matching your filters

Phase I Study Evaluating Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

Background: Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors are often treated using a hepatic arter…

Colorectal NeoplasmsNeoplasmsIntrahepatic Cholangiocarcinoma+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07715903

Evaluation of Diagnostic Accuracy and Clinical Performance of the UIICORE BSI Test

This study is designed to evaluate the clinical performance of the UllCORE BSI Test, an investigational molecular diagnostic test intended to detect microorgan…

Blood Stream InfectionBlood Stream InfectionsSepsis+2 more

Estimated

~$10 – $1,050

Deepull Diagnostics S.L.NCT07859852

Potential Impact of the COVID -19 Pandemic on Financial Toxicity in Breast Cancer Surgical Patients: The Impact on Out of Pocket Costs, Lost Wages and Economic Strain

This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast s…

Breast Ductal Carcinoma In SituCOVID-19 InfectionHereditary Breast Carcinoma+1 more

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT04169542

Phase 3

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell …

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma+18 more

Estimated

Phase 3

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patie…

Metastatic Dedifferentiated LiposarcomaMetastatic Undifferentiated Pleomorphic SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06422806

Phase 1

A Phase 1/2 Clinical Trial of the Novel Topoisomerase I Inhibitor PEEL-224 as a Single Agent and in Combination With Vincristine and Temozolomide in Children With Refractory, Progressive or Relapsed Solid Tumors

The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vi…

Refractory Solid TumorsRelapsed Solid TumorsRelapsed Neuroblastoma+3 more

Estimated

~$10 – $7,500

Theodore LaetschNCT06721689

Phase 3

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depem…

Pulmonary Disease, Chronic Obstructive

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT06961214

Observational

Utilizing Smart Speaker Technology to Deliver Parenting Education Support to Parents of Young Children

The goal of this clinical trial is to learn whether Talk Parenting, a voice-based program delivered through an Amazon Echo Dot (Alexa), can help parents and ca…

Parenting PracticesSelf EfficacyStress+4 more

Estimated

~$10 – $8,750

Oregon Research Behavioral Intervention Strategies, Inc.NCT07462052

Phase 2

Protocol EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II

This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitax…

Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaPeritoneal Carcinomatosis

Estimated

~$10 – $7,500

ECOG-ACRIN Cancer Research GroupNCT07001748

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network (STOP-VTE)

This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Re…

Malignant Digestive System NeoplasmMalignant Female Reproductive System NeoplasmMalignant Genitourinary System Neoplasm

Estimated

~$10 – $750

Wake Forest University Health SciencesNCT07215624

Phase 3

A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer

This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer…

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06524544

Phase 1

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this…

Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Anal CanalColorectal Cancer+8 more

Estimated

~$10 – $8,750

Bicara TherapeuticsNCT04429542